Early-goal Directed Automated Red Blood Cell Exchange for Acute Chest

Status Not yet recruiting

Clinical Trial Summary

Sickle cell disease (SCD) is characterized by recurrent vaso-occlusive pain crisis (VOC), which may evolve to acute chest syndrome (ACS), the most common cause of death among adult patients with SCD. Currently, there is no etiologic treatment to abort ACS. Therefore, management of ACS mostly involve a symptomatic approach including in routine, and as per recommendations, hydration, analgesics, supplemental oxygen, and transfusion. The polymerisation of sickle haemoglobin (HbS) is one major feature in the pathogenesis of vaso-occlusion. Current guidelines recommend red blood cell exchange transfusion (REX) in patients with severe ACS in order to improve oxygenation and reduce HbS concentration to blunt sickling. REX is often preferred over simple transfusion in this setting because it rapidly reduces HbS without raising final haematocrit. There are currently two methods for REX: manual (with sequential phlebotomies and transfusions) or automated (erythrocytapheresis). The former allows a sober use of red blood cell packs, while the latter achieves haematological targets (HbS and haematocrit) quickly and more consistently, but requires a special equipment and trained staff. As a result of inflammation and intravascular hemolysis, the plasma of patients with ACS may also contain several components that promote vaso-occlusion, lung injury and organ failure, including cytokines (e.g., IL-6), free haemoglobin and free haem. Conversely, it is depleted in haptoglobin and hemopexin, which normally bind to and clear cell-free haemoglobin. The addition of therapeutic plasma exchange to erythrocytapheresis during automated REX may therefore have a dual beneficial effect in patients with overt intravascular hemolysis: i) deplete the inflammatory mediators and products of hemolysis; ii) replete haptoglobin and hemopexin. REX modalities (automated vs manual) have not been tested during ACS. The hypothesis is that early-goal directed automated REX may accelerate the resolution of severe ACS as compared to manual REX.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06214845
Study type	Interventional
Source	Assistance Publique - Hôpitaux de Paris
Contact	Armand MEKONTSO DESSAP
Phone	+33 1 45 17 85 11
Email	armand.dessap@aphp.fr
Status	Not yet recruiting
Phase	N/A
Start date	March 1, 2024
Completion date	September 1, 2026

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02630394` - A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease	Phase 1
Active, not recruiting	`NCT04170348` - Daily Vitamin D for Sickle-cell Respiratory Complications	Phase 2
Recruiting	`NCT03498105` - Utility of the Cardiac Electrical BiomarkerDisease
Terminated	`NCT02098993` - Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome	Phase 2
Completed	`NCT02187445` - Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial	Phase 1
Completed	`NCT01089439` - Nitric Oxide Therapy for Acute Chest Syndrome in Sickle Cell Disease Children	Phase 2
Completed	`NCT03919266` - Combined Use of a Respiratory Broad Panel Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Hospitalized Sickle-cell Adults With Acute Chest Syndrome.	N/A
Terminated	`NCT01589926` - Bi-Level Positive Airway Ventilation for Acute Chest Syndrome	N/A
Completed	`NCT01041339` - ST Elevation in Acute Chest Pain; Could Measurement of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) be Helpful to the Clinician?	N/A
Completed	`NCT03250585` - sPLA2 in EBC During Acute Chest Syndrome
Completed	`NCT03805581` - Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome	Phase 2
Recruiting	`NCT03032055` - Validation of a Predictive Score of Acute Chest Syndrome
Terminated	`NCT03820466` - Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin	Phase 3
Completed	`NCT00748423` - Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study)	Phase 2/Phase 3
Completed	`NCT00434473` - IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome	Phase 2
Completed	`NCT02580773` - Therapeutic Anticoagulation Strategy for Acute Chest Syndrome	Phase 3
Completed	`NCT01443728` - Vitamin D for Sickle-cell Respiratory Complications	Phase 2
Recruiting	`NCT05640271` - Tocilizumab for Acute Chest Syndrome	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Early-goal Directed Automated Red Blood Cell Exchange for Acute Chest Syndrome in Sickle Cell Disease — ARCAD

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms